Tags

Type your tag names separated by a space and hit enter

Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma.
Am J Clin Pathol. 2009 Nov; 132(5):728-32.AJ

Abstract

Presence of normal plasma cells (PCs), hemodilution of bone marrow aspirate, and changes in the immunophenotype are important considerations in minimal residual disease (MRD) assessment in multiple myeloma (MM). We evaluated 124 subjects-107 with MM, 11 with Hodgkin lymphoma, and 6 allogeneic stem cell transplantation donors-for the immunophenotype of neoplastic, reactive, and normal PCs respectively. Of the patients with MM, 36 were evaluated for MRD and 23 for a change in immunophenotype after chemotherapy. The immunophenotype of normal and reactive PCs was similar and differed from that of neoplastic PCs with respect to CD19, CD45, CD56, CD52, CD20, and CD117. At least 2 antigens were aberrantly expressed in all cases and 3 in 90.7% of MM cases. A change in the immunoprofile of PCs was observed in 18 (78%) of 23 cases. By using flow cytometry, we detected MRD in all samples, and a neoplastic PC index (percentage of neoplastic PCs/total bone marrow PCs) of less than 30 could differentiate immunofixation (IFx)- from IFx+ samples (complete and partial responders, respectively).

Authors+Show Affiliations

Laboratory Oncology Unit, Dr. B.R. AIRCH, All India Institute of Medical Sciences, New Delhi.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19846814

Citation

Gupta, Ritu, et al. "Flow Cytometric Immunophenotyping and Minimal Residual Disease Analysis in Multiple Myeloma." American Journal of Clinical Pathology, vol. 132, no. 5, 2009, pp. 728-32.
Gupta R, Bhaskar A, Kumar L, et al. Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma. Am J Clin Pathol. 2009;132(5):728-32.
Gupta, R., Bhaskar, A., Kumar, L., Sharma, A., & Jain, P. (2009). Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma. American Journal of Clinical Pathology, 132(5), 728-32. https://doi.org/10.1309/AJCP1GYI7EHQYUYK
Gupta R, et al. Flow Cytometric Immunophenotyping and Minimal Residual Disease Analysis in Multiple Myeloma. Am J Clin Pathol. 2009;132(5):728-32. PubMed PMID: 19846814.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma. AU - Gupta,Ritu, AU - Bhaskar,Archana, AU - Kumar,Lalit, AU - Sharma,Atul, AU - Jain,Paresh, PY - 2009/10/23/entrez PY - 2009/10/23/pubmed PY - 2009/11/18/medline SP - 728 EP - 32 JF - American journal of clinical pathology JO - Am. J. Clin. Pathol. VL - 132 IS - 5 N2 - Presence of normal plasma cells (PCs), hemodilution of bone marrow aspirate, and changes in the immunophenotype are important considerations in minimal residual disease (MRD) assessment in multiple myeloma (MM). We evaluated 124 subjects-107 with MM, 11 with Hodgkin lymphoma, and 6 allogeneic stem cell transplantation donors-for the immunophenotype of neoplastic, reactive, and normal PCs respectively. Of the patients with MM, 36 were evaluated for MRD and 23 for a change in immunophenotype after chemotherapy. The immunophenotype of normal and reactive PCs was similar and differed from that of neoplastic PCs with respect to CD19, CD45, CD56, CD52, CD20, and CD117. At least 2 antigens were aberrantly expressed in all cases and 3 in 90.7% of MM cases. A change in the immunoprofile of PCs was observed in 18 (78%) of 23 cases. By using flow cytometry, we detected MRD in all samples, and a neoplastic PC index (percentage of neoplastic PCs/total bone marrow PCs) of less than 30 could differentiate immunofixation (IFx)- from IFx+ samples (complete and partial responders, respectively). SN - 1943-7722 UR - https://www.unboundmedicine.com/medline/citation/19846814/Flow_cytometric_immunophenotyping_and_minimal_residual_disease_analysis_in_multiple_myeloma_ L2 - https://academic.oup.com/ajcp/article-lookup/doi/10.1309/AJCP1GYI7EHQYUYK DB - PRIME DP - Unbound Medicine ER -